Bladder cancer: shedding light on the most promising investigational drugs in clinical trials
Irbaz Bin Riaz, Ahsan Masood Khan, James W.F. Catto, Syed A. Hussain
Abstract
: Approval of multiple ICIs, Enfortumab Vedotin (EV), Erdatfitinib and switch maintenance strategy with Avelumab, represent major advances in metastatic disease. ICI agents and EV are well poised to move forward for treating the early stages of bladder cancer. Finally, molecular characterization of the tumor offers hope for personalized treatment approaches.
Topics & Concepts
Clinical trialMedicineInvestigational DrugsBladder cancerUrothelial cancerOncologyAvelumabDiseaseCancerInternal medicineClinical researchIntensive care medicinePembrolizumabImmunotherapyBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesRenal cell carcinoma treatment